Join us for a free webinar covering the latest information for patients and caregivers.
We invite you to learn more about:
- Why CAR T-cell (chimeric antigen receptor T-cell) therapy shows promise for blood cancers
- Approved and emerging CAR T-cell therapies
- The future of CAR T-cell therapy for blood cancer patients
Iris Isufi, MD
Co-Director, Adult CAR-T-Cell Therapy Program
Yale Cancer Center/Smilow Cancer Hospital
Assistant Professor, Medicine
Yale University School of Medicine
New Haven, CT
Submit a question for Dr. Isufi to answer during the Q&A session.
Support for this program is provided by Bristol-Myers Squibb; CRISPR Therapeutics; Kite, a Gilead Company; and Novartis.